NXSL yields 30303.03% · ABBV yields 3.06%● Live data
📍 NXSL pulled ahead of the other in Year 1
Combined, NXSL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NXSL + ABBV for your $10,000?
NexTech FAS Technologies, Inc. engages in the design, manufacture, sale, and servicing of high-precision coating systems and advanced metrology and automation solutions for the semiconductor and flat panel display (FPD) industries. It also involves in the development FAS-Coat, a patented extrusion coating technology for aka spinless coating, slot die coating, and slit coating in the manufacturing process of FPD substrates. The company's products include Altair for testing the repeatability of systems that detect particles on the surface of substrates; Aludra, a reticle inspection system that employs light scattering technology to infer the presence of particles on a semiconductor reticle; Orion, a reticle inspection system, which provides inspection for semiconductor reticles and photomasks; FPDStar, an optical inspection system for identifying and mapping pattern, particle, and processing defects on FPD/TFT substrates; and NexTStar, an automated optical inspection system that represents breakthrough performance in FPD pattern, particle, and processing defect detection. Its products also comprise Pegasu, a wafer sorter series that provides standards-compliant user and automation interfaces; Proteus Reticle Load Port Upgrade kit, a hardware and software solution; and PST upgrades for wafer sorters. In addition, the company's FAS-Coat coating systems process substrates for the flat panel display, multi-chip module, solar cell, biomedical, and semiconductor industries. It was formerly known as NexTech Solutions, Inc. and changed its name to NexTech FAS Technologies, Inc. in July 2007. The company is headquartered in Austin, Texas.
Full NXSL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.